The Mycoplasma Testing Market is becoming increasingly important across pharmaceutical and biotechnology manufacturing because even low-level contamination can compromise cell cultures and production processes. Market Research Future estimates the market at USD 1.21 billion in 2025 and forecasts it to reach USD 3.52 billion by 2035 at a 10.20% CAGR.

Kits and reagents represent the leading product category because mycoplasma testing requires recurring consumables for routine quality-control programs. Testing services are also expanding as smaller biotechnology companies and manufacturers increasingly outsource specialized laboratory testing instead of maintaining fully equipped internal facilities.

Biopharmaceutical and biotechnology companies accounted for approximately USD 0.78 billion in market revenue in 2025. Contract manufacturing organizations are expected to grow rapidly as pharmaceutical companies increasingly outsource production and quality-control activities to specialized CDMOs with established testing infrastructure.

The regulatory environment remains a major market driver. Requirements surrounding biologics manufacturing and sterile processing are encouraging manufacturers to perform validated contamination testing at multiple stages, including cell-bank characterization, in-process monitoring, and final product release.

The market outlook is increasingly focused on faster and more automated detection. Rapid PCR platforms can shorten testing timelines compared with traditional culture-based approaches, while AI-supported laboratory analytics and automated workflows may further improve contamination monitoring and quality-control efficiency.

Gain valuable insights through comprehensive industry analysis:

Global Dental Software Market Volume

Global Dental Software Market Forecast

Global Dental Software Market Outlook

Global Dental Software Market Analysis

Germanium68 Gallium68 Generator Market Distribution